Baxter Announces $100 Million Investment In Biopharma Solutions Halle/Westfalen, Germany Sterile Fill/Finish Manufacturing Facility
Amount Raised
$100 Million
Round Type
Venture
DeerfieldDescription
Baxter International Inc. (NYSE:BAX), a global leader in sterile medication production and delivery, today announced an approximately $100 million expansion of its sterile fill/finish manufacturing facility located in Halle/Westfalen, Germany. This facility is operated by BioPharma Solutions (BPS), a business unit of Baxter that specializes in partnering with leading pharmaceutical and biotech companies on the development and contract manufacturing of drug product for parenteral (injectable) pharmaceuticals. Construction on the new manufacturing building is expected to begin in 2022 and be completed in 2024.
Who to call at Sterile Fill Finish Manufacturing Facility, and when
A new round usually means Sterile Fill Finish Manufacturing Facility is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Sterile Fill Finish Manufacturing Facility raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Sterile Fill Finish Manufacturing Facility, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Sterile Fill Finish Manufacturing Facility. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Sterile Fill Finish Manufacturing Facility raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Sterile Fill Finish Manufacturing Facility raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.